Norway Migraine Drugs Market Size & Outlook, 2023-2030

The migraine drugs market in Norway is expected to reach a projected revenue of US$ 147.1 million by 2030. A compound annual growth rate of 13.4% is expected of Norway migraine drugs market from 2024 to 2030.
Revenue, 2023 (US$M)
$61.2
Forecast, 2030 (US$M)
$147.1
CAGR, 2024 - 2030
13.3%
Report Coverage
Norway

Norway migraine drugs market highlights

  • The Norway migraine drugs market generated a revenue of USD 61.2 million in 2023 and is expected to reach USD 147.1 million by 2030.
  • The Norway market is expected to grow at a CAGR of 13.4% from 2024 to 2030.
  • In terms of segment, acute was the largest revenue generating treatment in 2023.
  • Preventive is the most lucrative treatment segment registering the fastest growth during the forecast period.


Migraine drugs market data book summary

Market revenue in 2023USD 61.2 million
Market revenue in 2030USD 147.1 million
Growth rate13.4% (CAGR from 2023 to 2030)
Largest segmentAcute
Fastest growing segmentPreventive
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationAcute, Preventive
Key market players worldwideGlaxoSmithKline, Pfizer Inc, AbbVie Inc, Amgen Inc, Eli Lilly and Co, Teva Pharmaceutical Industries Ltd, Biohaven Ltd, Johnson & Johnson, Bausch Health Companies Inc


Other key industry trends

  • In terms of revenue, Norway accounted for 1.1% of the global migraine drugs market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Europe, Germany migraine drugs market is projected to lead the regional market in terms of revenue in 2030.
  • Spain is the fastest growing regional market in Europe and is projected to reach USD 342.1 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Migraine Drugs Market Scope

Migraine drugs market segmentation & scope
Acute
Preventive
Triptans
Acetylcholine inhibitors/ neurotoxins
Ergot alkaloids
NSAIDs
Ditans
CGRP small molecule antagonists
CGRP monoclonal antibodies
Others
Oral
Injectable
Others
Pediatric
Adult
Geriatric
Prescription Drugs
Over-the-Counter (OTC) Drugs

Migraine Drugs Market Companies

Name Profile # Employees HQ Website

Norway migraine drugs market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to migraine drugs market will help companies and investors design strategic landscapes.


Acute was the largest segment with a revenue share of 63.24% in 2023. Horizon Databook has segmented the Norway migraine drugs market based on acute, preventive covering the revenue growth of each sub-segment from 2018 to 2030.


Reasons to subscribe to Norway migraine drugs market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Norway migraine drugs market databook

  • Our clientele includes a mix of migraine drugs market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Norway migraine drugs market , including forecasts for subscribers. This country databook contains high-level insights into Norway migraine drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Norway migraine drugs market size, by treatment, 2018-2030 (US$M)

Norway Migraine Drugs Market Outlook Share, 2023 & 2030 (US$M)

Norway migraine drugs market size, by treatment, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more